Eli Lilly's stock has skyrocketed by 593.18% since early 2020, reflecting a significant growth in market capitalization from $100 billion to $740 billion.
Recent initiatives include joining the Obesity Action Coalition to combat weight bias, exemplifying a shift from traditional pharma practices to broader societal responsibilities.
Eli Lilly is investigating the potential impacts of its obesity treatments, such as Zepbound, on employment rates, showcasing its commitment to comprehensive healthcare solutions.
With many analysts focusing on past growth for future projections, 24/7 Wall Street emphasizes a forward-looking approach to Eli Lilly's revenue and net income up to 2030.
Collection
[
|
...
]